Yanshan Huang (Y Huang)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 4

Top Topics

Cardiovascular Risk Factors

Glycemic Control

Editorial Comment

Top Venues

Diabetes, metabolic syndrome and obesity : targets and therapy

Journal of endocrinological investigation

Zhejiang Doer Biologics Corporation

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Zhejiang Doer Biologics Corporation Jan 01 2015

China

CEO

Jiangsu T-mab Biopharma Jan 01 2007 - Dec 31 2014

China

Senior VP

Publications

Yu Jian Shao, Yonglu Chen, Mingyue Zhu, Yuanyuan Liu, Chen Fang, Minjun Wang, Peng Sun, Weiling Fu, Jing Huang, Shimei Sheng, Yanshan Huang
DR10627, a Novel Dual Glucagon‑like Peptide‑1 and Gastric Inhibitory Polypeptide Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes Mellitus. Diabetes, metabolic syndrome and obesity : targets and therapy 17 (2024)
Yu Jian Shao, Yonglu Chen, Mingyue Zhu, Yuanyuan Liu, Chen Fang, Minjun Wang, Peng Sun, Weiling Fu, Jing Huang, Shimei Sheng, Yanshan Huang
DR10627, a Novel Dual Glucagon‑like Peptide‑1 and Gastric Inhibitory Polypeptide Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes Mellitus. Diabetes, metabolic syndrome and obesity : targets and therapy 17 (2024)
Yu Jian Shao, Yonglu Chen, Mingyue Zhu, Yuanyuan Liu, Chen Fang, Minjun Wang, Peng Sun, Weiling Fu, Jing Huang, Shimei Sheng, Yanshan Huang
DR10627, a Novel Dual Glucagon‑like Peptide‑1 and Gastric Inhibitory Polypeptide Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes Mellitus. Diabetes, metabolic syndrome and obesity : targets and therapy 17 (2024)
W Wang, X Wen, W Duan, X Wang, Y Chen, J Dong, Z Yang, J Fang, Z Zhou, G Yao, Y Fang, Yanshan Huang
DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus. Journal of endocrinological investigation 43 (5) (2019)